AstraZeneca could have a viable vaccine by November
The week started with good news from the US Food and Drug Administration (FDA). The federal agency issued an “emergency use authorization” (EUA) for convalescent plasma to be used as a treatment for hospitalized #COVID-19 cases.
According to the FDA, there is enough scientific evidence that showed that the antibody-rich plasma “may be effective,” and the possible benefits outweigh the potential risks. "Today’s action follows the FDA’s extensive review of the science and data generated over the past several months stemming from efforts to facilitate emergency access to convalescent plasma for patients as clinical trials to definitively demonstrate safety and efficacy remain ongoing."
This EUA will facilitate the distribution of convalescent plasma in the States and its use by healthcare providers.
Ahead of the presidential elections, this is seen as a victory for the Trump administration. Related to the subject, President #Trump is considering fast-tracking AstraZeneca’s COVID-19 vaccine candidate. He wants it done and available to Americans before the election.
AstraZeneca’s potential #vaccine produced a “strong immune response” during the first two phases of clinical trials. Currently, it has advanced to Phase III trials.
Following the announcement, the company's stock price rose by nearly 4%.
Read about the partnerships between the US government and pharmaceutical companies here!
Sources: marketwatch.com, thestreet.com
Gli utenti / lettori non dovrebbero fare affidamento esclusivamente sulle informazioni qui presentate e dovrebbero fare le proprie ricerche / analisi anche leggendo la ricerca reale sottostante. Il contenuto è generico e non tiene conto di circostanze personali individuali, esperienza di investimento o situazione finanziaria attuale.
Pertanto, Key Way Investments Ltd non accetta alcuna responsabilità per eventuali perdite di trader a causa dell'uso e del contenuto delle informazioni presentate nel presente documento. Le performance passate non sono un indicatore affidabile dei risultati futuri.